Cintirorgon
Cintirorgon (LYC-55716) is a first-in-class, selective and orally bioavailable RORγ agonist. Cintirorgon (LYC-55716) modulates gene expression of RORγ expressing T lymphocyte immune cells, resulting in enhanced effector function, as well as decreased immunosuppression, resulting in decreased tumor growth, and improved survival[1][2].
Product Specifications
CAS Number
[2055536-64-4]
Product Name Alternative
LYC-55716
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
ROR
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/LYC-55716.html
Concentration
10mM
Purity
99.95
Solubility
DMSO : ≥ 113.3 mg/mL|Ethanol : 100 mg/mL (ultrasonic)
Smiles
O=C(O)C(C)(C)C[C@@H]1OC2=CC=C(C3=CC(F)=CC(OC(F)F)=C3)C=C2N(S(=O)(C4=CC=CC(C(F)(F)F)=C4)=O)C1
Molecular Formula
C27H23F6NO6S
Molecular Weight
603.53
Precautions
H302, H315, H319, H335
References & Citations
[1]Lycera Announces Initiation of Phase 1/2a Study ARGON of Immuno-Oncology Candidate LYC-55716 in Patients with Advanced Solid Tumors. Jan 04, 2017.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
Lentiviral human BANF2 shRNA (UAS) - Lentiviral human BANF2 shRNA (UAS, RFP) plasmid